Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage,
which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between 64 and …

The discovery of hepatitis C virus (HCV) in 1989 permitted basic research to unravel critical
components of a complex life cycle for this important human pathogen. HCV is a highly …

The development and clinical implementation of direct-acting antivirals (DAAs) has
revolutionized the treatment of chronic hepatitis C. Infection with any hepatitis C virus (HCV) …

The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a
global problem despite advances in antiviral therapeutics. Current treatments fail to prevent …

Hepatitis C virus (HCV) envelope glycoprotein heterodimer, E1E2, plays an essential role in
virus entry and assembly. Furthermore, due to their exposure at the surface of the virion …

Hepatitis C virus (HCV) is a major global health burden accounting for around 170 million
chronic infections worldwide. Since its discovery, which dates back to about 30 years ago …

Hepatitis C virus (HCV) infection is a major health problem worldwide. It can cause liver
cirrhosis and hepatocellular carcinoma (HCC), making it a cause of morbidity from liver …

Hepatitis C virus (HCV) infection is still a significant global health problem despite
therapeutic advancements. Ribavirin and interferon therapy have been the sole available …

The E2 envelope glycoprotein is the primary target of human neutralizing antibody response
against hepatitis C virus (HCV), and is thus a major focus of vaccine and …

Hepatitis C virus (HCV) remains a public health problem of global importance, even in the
era of potent directly-acting antiviral drugs. In this chapter, I discuss immune responses to …